ArticleTherapeutic advances in medical oncology2024

BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib-resistant non-small-cell lung cancer.

Sun Min Lim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.